Dr. Carl William Moeller Ii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 988 Silas Deane Hwy, Wethersfield, CT 06109 Phone: 860-493-1950 Fax: 860-493-1961 |
Dr. Akshay Vasant Patel, DO Otolaryngology - Plastic Surgery within the Head & Neck Medicare: Accepting Medicare Assignments Practice Location: 988 Silas Deane Hwy, Wethersfield, CT 06109 Phone: 860-493-1950 Fax: 860-493-1961 |
Dr. Timothy John O'brien, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 988 Silas Deane Hwy, Wethersfield, CT 06109 Phone: 860-493-1950 Fax: 860-493-1961 |
News Archive
Leakage from the blood capillaries is a key mechanism leading to septic shock and multiorgan failure, which affect millions of patients annually worldwide. However, there is no effective way to inhibit the vessel leakiness. A new study by scientists at the University of Helsinki and Wihuri Research Institute demonstrates that vascular leakage can be inhibited by targeting vascular integrins.
Dr. Keiji Fukuda an expert at the Centres for Disease Control and Prevention is warning that the incident of the particularly lethal variation of influenza in Southeast Asia is probably far greater than has been reported so far.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
More than 14 percent of pregnant women were prescribed opioids (narcotics) for pain at some time during their pregnancy, according to a study posted to the online version of Anesthesiology.
When developing new drugs, monitoring cellular responses to candidate compounds is essential for assessing their efficacy and safety. Researchers from the RIKEN Center for Life Science Technologies report a new method to monitor and quantify the activity of gene promoters during the response to a drug, using the advanced gene expression analysis method CAGE followed by single-molecule sequencing.
› Verified 8 days ago